BLI VS RLYB Stock Comparison

Performance

BLI
10/100

BLI returned -83.56% in the last 12 months. Based on the other stocks in it's sector with an average return of -31.49%, it's performance is below average giving it a grade of 10 of 100.

RLYB
10/100

RLYB returned -59.08% in the last 12 months. Based on SPY's performance of -12.94%, its performance is below average giving it a score of 10 of 100.

Forecast

BLI
75/100

5 analysts offer 12-month price forecasts for BLI. Together, they have an average target of 0, the most optimistic forecast put BLI at 0 within 12-months and the most pessimistic has BLI at 0.

RLYB

"Forecast" not found for RLYB

Sentiment

BLI
62/100

BLI had a bullish sentiment score of 62.13% across Twitter and StockTwits over the last 12 months. It had an average of 5.53 posts, 0.77 comments, and 1.49 likes per day.

RLYB

"Sentiment" not found for RLYB

Technicals

BLI
11/100

BLI receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

RLYB
14/100

RLYB receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

BLI
10/100

BLI has missed earnings 7 times in the last 20 quarters.

RLYB
56/100

RLYB has missed earnings 2 times in the last 20 quarters.

Profit

BLI
10/100

Out of the last 10 quarters, BLI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

RLYB
10/100

Out of the last 15 quarters, RLYB has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BLI
42/100

BLI has had a lower than average amount of volatility over the last 12 months giving it a grade of 42 of 100.

RLYB
41/100

RLYB has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Berkeley Lights, Inc. Common Stock Summary

Nasdaq / BLI

Healthcare

Biotechnology

Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. Berkeley Lights, Inc. was incorporated in 2011 and is headquartered in Emeryville, California.

Rallybio Corporation Common Stock Summary

Nasdaq / RLYB

Healthcare

Biotechnology

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Power up your portfolio